Suppr超能文献

Extrapleural solitary fibrous tumor evidenced by Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient.

作者信息

Braga Ribeiro André Marcondes, Nascimento Thais Menezes Do, Lima Eduardo Nóbrega Pereira

机构信息

Department of Nuclear Medicine, A. C. Camargo Cancer Center, São Paulo, Brazil.

出版信息

World J Nucl Med. 2020 Jul 22;19(4):425-427. doi: 10.4103/wjnm.WJNM_18_20. eCollection 2020 Oct-Dec.

Abstract

Positron emission tomography/computed tomography (PET/CT) using Ga-labeled prostate-specific membrane antigen (Ga-PSMA) became an important tool in the prostate cancer (PC) diagnosis. Despite its high sensitivity and specificity, this method may produce false-positive findings, as indicated by previous studies. This case report aims to warn nuclear medicine physicians, oncologists, and urologists about the possibility of false-positive findings using this imaging modality, especially in patients who have already been diagnosed with other malignancies. A 69-year-old man, previously treated for an extrapleural solitary fibrous tumor (ESFT), underwent staging tests after a new diagnosis of high-risk PC. Ga-PSMA PET/CT imaging revealed an abnormal uptake in the prostate and in the right humerus. A biopsy was performed, and the pathology showed a lesion consisting of an ESFT metastasis. Diagnostic issues related to Ga-PSMA PET/CT imaging should be disseminated to help physicians make appropriate treatment choices for each patient and avoid unnecessary procedures.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/979d/7875026/70cfd9684247/WJNM-19-425-g001.jpg

相似文献

3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
10
[Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
Mol Imaging Biol. 2019 Jun;21(3):574-581. doi: 10.1007/s11307-018-1278-8.

本文引用的文献

2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.
Eur J Nucl Med Mol Imaging. 2018 May;45(5):860-877. doi: 10.1007/s00259-017-3922-y. Epub 2018 Jan 15.
4
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136. doi: 10.1007/s00259-017-3780-7. Epub 2017 Aug 1.
7
Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
J Nucl Med. 2015 May;56(5):668-74. doi: 10.2967/jnumed.115.154153. Epub 2015 Mar 19.
8
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Prostate. 2014 Feb;74(2):210-6. doi: 10.1002/pros.22742. Epub 2013 Oct 16.
9
Solitary fibrous tumor in the thigh: review of the literature.
J Cancer Res Clin Oncol. 2006 Feb;132(2):69-75. doi: 10.1007/s00432-005-0055-7. Epub 2005 Nov 9.
10
State-of-the-art approaches to detecting early bone metastasis in prostate cancer.
BJU Int. 2004 Aug;94(3):268-71. doi: 10.1111/j.1464-410X.2003.04960.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验